Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hospital de Clinicas de Porto Alegre
With
Federal University of Rio Grande do Sul
University of Sao Paulo
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Major depressive episode as part of bipolar I disorder or bipolar II disorder according to Fifth Edition of Diagnostic and Statistical Manual for Mental Disorders (DSM-5) and are able to provide written informed consent.
Montgomery-Asberg Depression Rating Scale (MADRS) score ≥ 12 and MADRS items 1 (Apparent Sadness) and 2 (Reported Sadness) scores ≥ 2 at baseline.
Young Mania Rating Scale (YMRS) ≤ 11.
Currently prescribed lithium or valproic acid and derivates (divalproex sodium, sodium valproate) or atypical antipsychotics at therapeutic dosage for at least 04 weeks before the baseline.
Females must test negative for pregnancy and must be using adequate birth control measures throughout the study.
You may not be if
Another concurrent mental or behavioral disorder that requires psychiatric attention in the past 6 months.
Young Mania Rating Scale (YMRS) score \> 12.
Current or past drug sensitivity/intolerance to cannabidiol.
Substance Use Disorder according to DSM-5 within past 6 months, except for nicotine Substance Use Disorder.
Clinically significant unstable medical illness, neurological disorders or inflammatory/autoimmune diseases.
Any autoimmune, inflammatory or neurologic disorders that requires treatment with steroidal anti-inflammatory medications or immunotherapy with biologic drugs.
Actively suicidal or homicidal risk.
Females who are pregnant or breastfeeding
Clareo Health | Cannabidiol as an Adjunctive Treatment for Bipolar Depression
